This year's annual scientific sessions of the American College of Cardiology (ACC; Bethesda, Maryland), held here in early March, included a newly launched meeting-within-a meeting focusing on interventional cardiology, a change that is indicative of the growing importance of device-based therapies in cardiovascular disease. Drug-eluting stents (DES) continue to play a key role in market expansion, and now dominate the field of percutaneous intervention (PCI) in the U.S. and, increasingly, in Europe.